US Lawmakers Sound Alarm Over China’s Growing Dominance in Pharma Supply Chain

The House Select Committee on China’s recent hearing, titled “From the Science Lab to the Medicine Cabinet,” has brought a long-simmering healthcare vulnerability into sharp focus: the deep-seated reliance of the American medical system on Chinese-manufactured ingredients. Representative John Moolenaar’s opening assertion that China is systematically “cornering the market” reflects a growing bipartisan consensus in Washington that pharmaceuticals have become the latest frontier in a broader geopolitical struggle for supply chain dominance. This is no longer viewed merely as a trade imbalance but as a fundamental national security threat, where the availability of essential antibiotics and advanced biologics is tied to the industrial policy of a strategic adversary.

Lawmakers like Florida Republican Neal Dunn are drawing direct parallels between the pharmaceutical sector and other critical industries where China has successfully established dominance, such as rare earth minerals, semiconductors, and electric vehicles. The strategy described by the committee involves heavy state subsidies, the systematic displacement of international competitors through aggressive pricing, and a steady climb up the value chain. While China’s initial entry into the market focused on low-margin generic ingredients, it is now aggressively targeting the “cutting-edge biotech pipeline.” This shift suggests that the U.S. could lose its long-standing lead in medical innovation if it fails to address the structural advantages China has built through decades of centralized industrial planning.

“

According to UBS estimates, China’s pharmaceutical and medical device sectors are expected to generate more than $2.1 trillion in revenue by 2030.

The scale of China’s ambition is underscored by recent financial projections that should serve as a wake-up call for domestic healthcare leaders. According to UBS estimates, China’s pharmaceutical and medical device sectors are expected to generate more than $2.1 trillion in revenue by 2030. This represents a staggering 50% increase from 2024 levels, driven by a combination of an aging domestic population and a concerted push for global market share. For U.S. healthcare providers and Health IT firms, this trend signals a future where the cost and availability of essential medicines are increasingly decoupled from domestic market forces and instead influenced by Beijing’s strategic objectives.

However, the exact extent of this dependence remains a subject of intense debate among experts. Marta Wosinska, a witness at the hearing and a prominent healthcare researcher, cautioned that some widely cited statistics might overstate the immediate crisis. While a 2025 Brookings Institution report estimated that China accounts for roughly 25% of the drug volume sold in the U.S., the complexity of global supply chains makes precise measurement difficult. Many drugs finished in third-party countries like India or Germany still rely on Chinese-made chemical precursors. This “hidden” dependence means that even if a final product is not labeled “Made in China,” its production remains vulnerable to disruptions in Chinese exports or shifts in Beijing’s trade policy.